Robert Gamble Talks about the Challenges Payers and Providers Face in Oncology Management

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Yearly dental visits were associated with fewer secondary strokes, and hyperthyroidism was flagged as a key CVST risk factor in women.

Shervin Badihian, MD, explains how digital health tools can help boost poststroke activity via reminders, goals, feedback, and gamification.